VCEL (Vericel) Debt-to-Equity : 0.38 (As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Vericel Debt-to-Equity?

Vericel's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.1 Mil. Vericel's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $91.3 Mil. Vericel's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $257.5 Mil. Vericel's debt to equity for the quarter that ended in Sep. 2024 was 0.38.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vericel's Debt-to-Equity or its related term are showing as below:

VCEL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.29 Max: 0.82
Current: 0.38

During the past 13 years, the highest Debt-to-Equity Ratio of Vericel was 0.82. The lowest was 0.00. And the median was 0.29.

VCEL's Debt-to-Equity is ranked worse than
70.19% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs VCEL: 0.38

Vericel Debt-to-Equity Historical Data

The historical data trend for Vericel's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Debt-to-Equity Chart

Vericel Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.25

0.40

0.29

0.25

0.39

Vericel Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.42	0.39	0.39	0.39	0.38

Competitive Comparison of Vericel's Debt-to-Equity

For the Biotechnology subindustry, Vericel's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vericel's Debt-to-Equity falls into.

Vericel Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vericel's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.187	+	81.856)	/	225.952
	=	0.39

Vericel's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.119	+	91.344)	/	257.472
	=	0.38

Vericel (NAS:VCEL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vericel Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vericel's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Executives

Paul K Wotton	director	C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Zerbe Robert L Md	director
Dominick Colangelo	director, officer: President and CEO	1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Kevin F Mclaughlin	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Sean C. Flynn	officer: SVP, General Counsel	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Mara Joseph Anthony Jr	officer: Chief Financial Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal	officer: Principal Accounting Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Michael Halpin	officer: Chief Operating Officer	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Lisa Wright	director	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sandra Pennell	officer: VP and Corporate Controller	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel	officer: CFO & VP , Corp. Development	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando	officer: Chief Operating Officer	P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105